• Publications
  • Influence
Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods.
TLDR
No method appears to systematically under- or overestimate LVEF to any major extent, and these findings have important implications for the investigation of heart failure and for the practice and reporting of echocardiography. Expand
Levosimendan: a new era for inodilator therapy for heart failure?
TLDR
Preliminary observations suggest that hemodynamic changes are associated with symptomatic benefit and a reduction in morbidity and mortality in patients with severe heart failure caused by left ventricular systolic dysfunction, compared with placebo in one study and dobutamine in another. Expand
The evidence for β blockers in heart failure
TLDR
Evidence has accumulated to show that β blockers, when used in addition to angiotensin converting enzyme inhibitors, also reduce mortality in heart failure, and there is no evidence of heterogeneity between trials. Expand
Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure
TLDR
Preliminary observations suggest that a single infusion of levosimendan lasting 6 to 24 h in patients with severe heart failure due to left ventricular systolic dysfunction results in hemodynamic changes, symptomatic benefit and a reduction in morbidity and mortality over the following 2 to 4 weeks compared with placebo in one study and with dobutamine in another. Expand
Beta-blockers for chronic heart failure: from prejudice to enlightenment.
TLDR
Beta-blockade should be added to conventional therapy such as diuretics, ACE inhibitors, and digoxin, as this was the approach used in the major trials. Expand
Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression.
TLDR
There are major theoretical and practical concerns about the use of anti-coagulant, anti-platelet and statin therapy in patients with heart failure as well as major theoretical benefits but trials addressing all these areas are under way, which should put the management of coronary disease in patientsWith heart failure on a firm evidence-based footing. Expand
Validation of an echocardiographic wall motion index in heart failure due to ischaemic heart disease
TLDR
This study aimed to examine the application of a wall motion index (WMI) method, using a nine‐segment LV model in patients with chronic heart failure (CHF) due to IHD. Expand
Carvedilol for Heart Failure: Clinical Trials in Progress
TLDR
The most important study for clinical practice is the COMET study, comparing metoprolol and carvedilol in a head-to-head comparison, which addresses one of the most hotly debated issues surrounding the recent spate of positive clinical trials with betablockers in heart failure. Expand
Heart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression.
TLDR
There are major theoretical and practical concerns about the use of anti-coagulant, anti-platelet and statin therapy in patients with heart failure as well as major theoretical benefits but trials addressing all these areas are under way, which should put the management of coronary disease in patientsWith heart failure on a firm evidence-based footing. Expand
Left ventricular systolic dysfunction in a cardiac transplant recipient treated with carvedilol
TLDR
A 49‐year‐old cardiac transplant recipient with idiopathic left ventricular systolic dysfunction was treated with carvedilol and after 8 months, his ejection fraction had increased from 14 to 30% with an associated improvement in symptoms. Expand
...
1
2
...